Viable Vaccine Candidate for COVID-19 Developed Using Proprietary Plant-based TechnologyMarch 18, 2020
Canadian biopharmaceutical company Medicago announced that it has successfully produced a Virus-Like Particle (VLP) of the coronavirus 20 days after obtaining the SARS-CoV-2 (the virus causing the COVID-19 disease) genetic sequence. Medicago produced the VLP using proprietary plant-based technology. The production of the VLP is the first step in developing a vaccine for COVID-19 which will now undergo preclinical testing for safety and efficacy.
Medicago was able to produce the VLP fast using plant-based technology, a proprietary potential alternative to traditional egg-based production systems. Traditional vaccine production requires using a lot of eggs. However, this practice is not only expensive but also takes a long time and is far from perfect.
Medicago does not work with a live virus but uses plants. Their technology inserts a genetic sequence into Agrobacterium, a soil bacterium, which is taken up by plants. The plant begins to produce the protein that can then be used as a vaccine. If the virus begins to mutate, as is expected for COVID-19, they can just update the production using new plants.
"That's the difference between us and egg-based methods," Medicago CEO Bruce Clark said. "We go directly to producing the vaccine or the antibody without having to propagate the virus." Using plants and genetically engineered Agrobacterium works faster than eggs also makes the vaccine much easier to produce at scale.
You might also like:
- GM Tobacco Expressing Cervical Cancer Vaccine
- Hepatitis B Vaccine from Transgenic Rice
- Pocket K No. 26: Molecular Pharming and Biopharmaceuticals
Biotech Updates is a weekly newsletter of ISAAA, a not-for-profit organization. It is distributed for free to over 22,000 subscribers worldwide to inform them about the key developments in biosciences, especially in biotechnology. Your support will help us in our mission to feed the world with knowledge. You can help by donating as little as $10.
See more articles:
News from Around the World
- Multiple Approaches Necessary to Achieve Global Targets to Combat Poverty and Hunger
- Ugandan President Ready to Sign GMO Bill into Law
- Study Documents Ghana's Public Perception Towards GM Food, Labeling
- Canada Celebrates 25 Years of GM Approvals
- UPenn Develops Lettuce That Stimulates Bone Building Cells
- First Comprehensive Map of the Arabidopsis Proteome Now Available
- European Consumers Exposed to Consistent Fear-Mongering from Anti-Biotech Groups for Two Decades
- Drought Tolerant Potato Developed thru Overexpression of GhABF2
- CRISPR-Cas9 Used to Develop Marker-free Carotenoid-enriched Rice
- Viable Vaccine Candidate for COVID-19 Developed Using Proprietary Plant-based Technology
Read the latest:
- Biotech Updates (September 20, 2023)
- Gene Editing Supplement (September 13, 2023)
- Gene Drive Supplement (February 22, 2023)
Subscribe to BU: